LeukoStrat® KMT2A + MRD Assay
Hematologic Cancers (e.g., AML)
Development/ValidationActive
Key Facts
About InVivoScribe
Founded in 1999 and headquartered in San Diego, CA, InVivoScribe has established itself as a pioneer in precision diagnostics for hematologic malignancies. The company operates a dual business model, offering both a portfolio of regulated diagnostic products (CE-IVD, IVD) and a global network of CLIA-certified clinical laboratories (LabPMM). Its core strength lies in its proprietary assays for biomarkers like FLT3 and NPM1, its role as a streamlined CDx development partner for pharma, and its leadership in MRD testing, positioning it at the intersection of diagnostics, personalized medicine, and drug development support.
View full company profile